


Atrasentan

Cat. No.:	HY-15403		
CAS No.:	173937-91-2		
Molecular Formula:	C ₂₉ H ₃₈ N ₂ O ₆ S		
Molecular Weight:	542.69		
Target:	Endothelin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (184.27 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.8427 mL	9.2134 mL	18.4267 mL
	5 mM	0.3685 mL	1.8427 mL	3.6853 mL
	10 mM	0.1843 mL	0.9213 mL	1.8427 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Atrasentan (ABT-627) is an endothelin receptor antagonist with IC₅₀ of 0.0551 nM for ET_A^[1].

IC₅₀ & Target

IC₅₀: 0.055 nM (ET_A)

In Vitro

Atrasentan (ABT-627, 0-50 μM) significantly inhibits LNCaP and C4-2b prostate cancer cell growth. ABT-627 in combination with Taxotere elicits a significantly greater loss of viable prostate cancer cells relative to either agent alone and shows greater degree of down-regulation of the NF-κB DNA binding activity^[2]. Atrasentan profoundly induces several CYPs and drug transporters (e.g. 12-fold induction of CYP3A4 at 50 μM). It is a moderate P-gp inhibitor (IC₅₀ in P388/dx cells=15.1±1.6 μ

M) and a weak BCRP inhibitor (IC_{50} in MDCKII-BCRP cells= $59.8 \pm 11 \mu\text{M}$)^[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atrasentan (3 mg/kg, p.o.) inhibits the pressor response induced by big endothelin-1 (1 nmol/kg) in pithed rats^[1].
Atrasentan (ABT-627, 10 mg/kg, i.p.) as well as Taxotere alone inhibited the C4-2b tumor growth within the bone environment to some extent in the SCID-hu model^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[2]

Cells are incubated and treated with Atrasentan. They are then washed twice with PBS and lysed in ice-cold lysis buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium PPI, 1 mM β -glycerophosphate, 1 mM sodium orthovanadate, 1 $\mu\text{g}/\text{mL}$ leupeptin, and 1 mM PMSF]. The extracts are centrifuged to remove cellular debris, and the protein content of the supernatants is determined using the bicinchoninic acid (BCA) protein assay reagent. Proteins (150 μg) are incubated with gentle rocking at 4°C overnight with immobilized Akt antibody cross-linked to agarose hydrazide beads. After the Akt is selectively immunoprecipitated from the cell lysates, the immunoprecipitated products are washed twice with lysis buffer and twice with kinase assay buffer [25 mM Tris (pH 7.5), 10 mM MgCl_2 , 5 mM β -glycerol phosphate, 0.1 mM sodium orthovanadate, 2 mM DTT] and then resuspended in 40 μL of kinase assay buffer containing 200 μM ATP and 1 μg GSK-3 α/β fusion protein. The kinase assay reaction is allowed to proceed at 30°C for 30 min and stopped by the addition of Lamelli SDS sample buffer. Reaction products are resolved by 10% SDS-PAGE, followed by Western blotting with antiphosphorylated GSK-3 α/β antibody. For analysis of the total amount of Akt, 40 μg of protein from the lysate samples are resolved by 10% SDS-PAGE, followed by Western blotting with anti-Akt antibody.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay ^[2]

All three prostate cancer cell lines (LNCaP, C4-2b, and PC-3 cells) are seeded at a density of 3×10^3 cells per well in 96-well microtiter culture plates. After overnight incubation, the medium is removed and replaced with a fresh medium containing different concentrations of ABT-627 (0-50 μM) diluted from a 10-mM stock. After 72 h of incubation with drug, 20 μL of MTT solution (5 mg/mL in PBS) are added to each well and incubated further for 2 h. Upon termination, the supernatant is aspirated and the MTT formazan formed by metabolically viable cells is dissolved in isopropanol (100 μL). The plates are mixed for 30 min on a gyratory shaker, and the absorbance is measured at 595 nm on a plate reader.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

YM598 (0.3, 1, and 3 mg/kg), atrasentan (0.3, 1, and 3 mg/kg), or 0.5% methyl cellulose as vehicle is orally administered to rats with a dosing cannula. Dosing volume of the test substances and vehicle is set at 5 mL/kg. Approximately 20 min after administration of compounds, the rats are anesthetized with sodium pentobarbital, and then pithed and ventilated 30 min after dosing. Approximately 1 h after oral administration of compounds, big endothelin-1 (1 nmol/kg) is intravenously administered, and blood pressure is measured. In these two experiments, the dose of test compound that cause 50% inhibition (ID_{50}) of the big endothelin-1-induced increase in diastolic blood pressure is determined by linear regression analysis.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Commun Biol. 2022 Jul 28;5(1):750.
- Eur J Pharmacol. 2019 Mar 12;852:142-150.
- Mol Immunol. 2019 Oct;114:10-18.
- J Vet Intern Med. 2015 Nov;29(6):1584-94.
- Department Veterinary Clinical Medicine. University of Illinois. 2015.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. *Eur J Pharmacol.* 2004 Sep 13;498(1-3):171-7.
- [2]. Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. *Cancer Res.* 2007 Apr 15;67(8):3818-26.
- [3]. Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. *Cancer Chemother Pharmacol.* 2011 Oct;68(4):1093-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA